cd19 car-t trial design
Chronic Disease Management Trials Hinge on One Crucial Design Flaw
$600 billion in annual prescription drug spending highlights why chronic disease management trials must address a core design flaw: the lack of biomarker-driven, basket-style enrollment that captures shared immunologic mechanisms across autoimmune diseases. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult